ABVC BioPharma, Inc.
ABVC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 100% | – | – | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $2 | $1 | $0 |
| SG&A Expenses | $2 | $2 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $1 | $0 |
| Operating Income | -$1 | -$2 | -$1 | -$0 |
| % Margin | -146.8% | – | – | -16,996.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$1 | -$2 | -$1 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | -$1 | $0 |
| % Margin | -156.6% | – | – | 11,663.5% |
| EPS | -0.054 | -0.13 | -0.06 | 0.017 |
| % Growth | 58.8% | -116.7% | -448.8% | – |
| EPS Diluted | -0.054 | -0.13 | -0.06 | 0.017 |
| Weighted Avg Shares Out | 23 | 17 | 15 | 13 |
| Weighted Avg Shares Out Dil | 23 | 17 | 15 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$1 | -$0 |
| % Margin | -161% | – | – | -1,530.5% |